Loading
A phase 2 trial of Dostarlimab and Carboplatin in endometrial cancer, run by GlaxoSmithKline, now recruiting.
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) is a phase 2 interventional study registered as NCT07108270 by GlaxoSmithKline, with 30 participants planned, started 2025-11-27 and due to reach its primary completion in 2030-03-31. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.
Shares Dostarlimab, GSK, Platinum agents, Carboplatin and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Platinum agents, Carboplatin and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Carboplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares GSK, Endometrial cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, GSK, Endometrial cancer and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.